Panolos Bioscience is a frontrunner in structural biology-based protein design and development, with a focus on multi-specific drug development. We specialize in creating anti-angiogenic therapeutics targeting cancer, autoimmune, and rare diseases. Panolos Bioscience's alpha-ART platform is a groundbreaking approach that fuses VEGFR1(D2D3) to Fc, creating a platform for attaching effector moieties to develop mono- or multi-specific therapeutics aimed at improving anti-cancer immunity and vascular normalization. This technology is pivotal in addressing the challenges faced in treating complex diseases like cancer, autoimmune, and metabolic disorders, which include unclear disease mechanisms and the difficulties of combining therapies for better patient outcomes.